Congressman Mark Pocan (WI) and Congressman Morgan Griffith, in exercising their oversight responsibilities over the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA), discovered that on August 16, 2018 HHS had rescinded the request for the kratom to be classified as a Schedule I substance under the Controlled Substances Act (CSA).
In the HHS letter to the Drug Enforcement Administration (DEA) HHS recommended that “mitragynine and 7-hydroxymitragynine not be controlled at this time, either temporarily or permanently, until scientific research can sufficiently support such an action.” The FDA had made a recommendation for scheduling of kratom on August 31, 2016 that was subsequently withdrawn by the DEA on October 13, 2016 for insufficiency of evidence to support the scheduling under the CSA, and FDA submitted its second recommendation on October 17, 2017 that has been withdrawn by HHS because the scientific research did not justify the scheduling.
More at PRNewswire.